

Application Serial No.: 10/824,005
Attorney Docket No. P-082-US3
Page 25 of 28

REMARKS

Applicants respectfully request that the above amendments be entered in this application prior to examination on the merits.

1. Status of the Claims

Claims 13-30 are currently pending. Claim 29 has been canceled. Claims 17 and 30 have been amended. Upon entry of the above amendments, Claims 13-28 and 30 are pending for examination on the merits.

2. Summary of the Amendments

In Claim 17, section (w) which recites a moiety of formula AB', has been amended to define R₅₀ as C₁₋₅alkyl, and to delete the term "analog".

Claim 29 has been canceled.

Claim 30 has been amended to delete the terms "chronic inflammatory disease, arthritis, and neoplasia."

No new matter is introduced by the above amendments.

Entry of the above amendments is respectfully requested.

3. Rejection of Claim 30, under 35 U.S.C. 112, first paragraph

Claim 30 has been rejected under 35 U.S.C. 112, first paragraph, allegedly because "the specification, while being enabling for the treatment of many of the diseases recited in claim 30, does not reasonably provide enablement for the treatment of neoplasia, chronic inflammatory disease and arthritis." The Office Action further continues: in particular, "there has been recited a method of treating neoplasia, chronic inflammatory disease and arthritis, but the specification is not enabled for such a scope."

Applicants respectfully disagree, however, in order to expedite allowance of this application, have amended Claim 30 such that it no longer recites "neoplasia, chronic inflammatory disease and arthritis."

Therefore, Applicants respectfully request that the rejection of Claim 30 under 35 U.S.C. 112, first paragraph be withdrawn.

Application Serial No.: 10/824,005
Attorney Docket No. P-082-US3
Page 26 of 28

4. Rejection of Claims 13-30 under 35 U.S.C. 112, second paragraph

Claims 13-30 have been rejected under 35 U.S.C. 112, second paragraph, as allegedly being indefinite for "failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention." Specifically, the Examiner has indicated that various terms are indefinite. For the following reasons, Applicants respectfully disagree.

(a) The Examiner has indicated that the term "substituted" is allegedly indefinite as used, for example, in terms such as "substituted alkyl," "substituted alkenyl," "substituted alkynyl," "substituted cycloalkyl," "substituted alkoxy," "substituted amino" and "substituted thioalkoxy."

In response, Applicants note that the definition of each of these terms is clearly and unambiguously set forth in Applicants' specification and therefore, one skilled in the art would clearly understand what is meant by each of these terms. For example, "substituted alkyl" is defined on page 39, line 25 through page 40, line 2; "substituted alkenyl" is defined on page 41, lines 23-31; "substituted alkynyl" is defined on page 42, line 25 through page 43, line 3; "substituted cycloalkyl" is defined on page 45, lines 10-18; "substituted alkoxy" is defined on page 40, line 30 through page 41, line 2; "substituted amino" is defined on page 44, lines 27-31; and "substituted thioalkoxy" is defined on page 47, line 27 of the specification as originally filed.

Accordingly, since each of these terms is clearly and unambiguously defined in the specification as filed, one skilled in the art would clearly understand what is meant by these terms. Therefore, Applicants respectfully request that this rejection be withdrawn.

(b) The Examiner has indicated that the term "heterocyclic" is allegedly indefinite. In response, Applicants respectfully note that the term "heterocycle" or "heterocyclic" is clearly and unambiguously defined on page 46, line 23 through page 47, line 13, of the specification as originally filed. Accordingly, one skilled in the art would clearly understand what is meant by this term and therefore, Applicants respectfully request that this rejection be withdrawn.

(c) The Examiner has indicated that the term "oxyacylamino" is allegedly not clear. In response, Applicants respectfully note that the term "oxyacylamino" is clearly and unambiguously defined on page 47, lines 19-22 of the specification as originally filed. Accordingly, one skilled in the art would clearly understand what is meant by this term and therefore, Applicants respectfully request that this rejection be withdrawn.

Application Serial No.: 10/824,005
Attorney Docket No. P-082-US3
Page 27 of 28

(d) The Examiner has indicated that the term "acyl" is indefinite. In response, Applicants respectfully note that the term "acyl" is clearly and unambiguously defined on page 43, lines 18-22 of the specification as originally filed. Accordingly, one skilled in the art would clearly understand what is meant by this term and therefore, Applicants respectfully request that this rejection be withdrawn.

(e) The Examiner has objected to the use of both the terms "*heteroaryl*" and "*heterocyclic*" for substituent choices for R, R', and R" (in the last paragraph of Claim 13). Specifically, the Examiner has suggested that, since the term "*heterocyclic*" is allegedly a broader term, the use of "*heteroaryl*" seems redundant."

In response, Applicants respectfully note that the terms "*heteroaryl*" and "*heterocyclic*" are defined on page 46, beginning on lines 02 and 23, respectively. Applicants further note that "*heteroaryl*" refers to an "aromatic group" and "*heterocyclic*" refers to a "saturated or unsaturated group." Accordingly, one skilled in the art would clearly understand the distinction between these terms. Therefore, Applicants respectfully suggest that both terms are appropriate. Accordingly, Applicants respectfully request that this rejection be withdrawn.

(f) The Examiner has indicated that the term "analog" is allegedly indefinite. This term has been deleted from Claim 17 and therefore, this rejection is moot.

(g) The Examiner has indicated that the scope of Claim 29, which recites "a method of treating a disease or medical disorder mediated by a protein kinase", is allegedly unknown. Claim 29 has been canceled and therefore, this rejection is moot.

For the foregoing reasons, Applicants respectfully request that the rejections previously applied to Claims 13-30 under 35 USC §112, second paragraph, be withdrawn.

4. Return of initialed PTO/SB/08a Forms

Applicants wish to thank the Examiner for the prompt return of the initialed PTO/SB/08a forms submitted as part of the Information Disclosure Statement filed on July 7, 2004.

Application Serial No.: 10/824,005
Attorney Docket No. P-082-US3
Page 28 of 28

BEST AVAILABLE COPY

Applicants respectfully submit that this application is now in condition for allowance.
Should there be any remaining issues that can be resolved by telephone, the Examiner is respectfully requested to telephone the undersigned agent at (650) 808-6144.

Respectfully submitted,

Date: January 21, 2005

By Joyce G. Cohen
Joyce G. Cohen, Reg. No. 44,622

THERAVANCE, INC.
Attn: Legal Dept.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078